Database : MEDLINE
Search on : dizziness [Words]
References found : 17301 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1731 go to page                         

  1 / 17301 MEDLINE  
              next record last record
select
to print
Photocopy

[PMID]: 29483487
[Au] Autor:Xu F; Xiao Z; Peng L; Qin C; Yang G; Gu J; Zuo Y
[Ad] Address:Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland).
[Ti] Title:A Rare Case of Cardiac Calcified Amorphous Tumor: Multi-Modality Imaging Evaluation.
[So] Source:Am J Case Rep;19:214-217, 2018 Feb 27.
[Is] ISSN:1941-5923
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND Cardiac calcified amorphous tumors (CAT) are rarely presented and featured as calcification and eosinophilic amorphous material in dense collagenous fibrous tissue. CASE REPORT Our case report describes a 47-year-old man presenting cardiac CAT with only chronic cough and occasional dizziness. Preoperative multi-modality imaging was used to evaluate it and postoperative histological study was used to confirm the diagnosis. The mass was resected and the patient was fully recovered and discharged on the 7th postoperative day. In the 1-year follow-up, transthoracic echography showed no further pathological changes. CONCLUSIONS Cardiac CAT is a non-neoplastic cardiac tumor of unknown etiology. The tumor is commonly an incidental finding and the treatment of choice is complete surgical resection. In this case, we found that that multi-modality images were helpful in evaluating and diagnosing the cardiac CAT.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Process

  2 / 17301 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29409850
[Au] Autor:Kongkaew C; Scholfield NC; Dhippayom T; Dilokthornsakul P; Saokaew S; Chaiyakunapruk N
[Ad] Address:Centre for Safety and Quality in Health, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; Research Department of Practice and Policy, School of Pharmacy, University College London, UK. Electronic address: chuenjid@googlemail.com.
[Ti] Title:Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham for menopausal women: A systematic review of clinical trials and the way forward.
[So] Source:J Ethnopharmacol;216:162-174, 2018 Apr 24.
[Is] ISSN:1872-7573
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham (commonly termed P. mirifica, PM) growing in upland Thailand has a long history as a postmenopausal rejuvenant therapy for indigenants. Its amelioration of menopause symptoms in clinical trials was assessed. MATERIALS AND METHODS: International and Thai databases were searched from inception to February 2017. Clinical trials investigating effects of PM menopausal or postmenopausal women were included. Outcomes were self-reported menopausal symptoms, serum reproductive hormones, urino-genital tract function, and bone surrogates. Methodological quality was assessed by Cochrane risk-of-bias v2.0, and a 22-parameter quality score based on the CONSORT checklist for herbal medicines. RESULTS: Eight studies (9 articles) used data from 309 menopausal patients. Five-studies demonstrated that PM was associated with climacteric scores reduced by ~50% compared to baseline. Other PM studies using limited numbers of placebo participants suggested improved vaginal and other urogenital tract symptoms. Bone alkaline phosphatase halved (suggesting lowered bone turnover). Variable serum reproductive hormone levels suggested menopausal status differed between studies. PM active ingredients and sources were not defined. Adverse event rates (mastodynia, vaginal spotting, dizziness) were similar in all groups (PM, conjugated equine estrogen, and placebos) but serum C-reactive protein doubled. These studies had design and reporting deficiencies, high risks of biases, and low quality scores. CONCLUSIONS: The efficacy of PM on menopausal symptoms remains inconclusive because of methodological short-comings especially placebo effects inherent in self-assessment/recall questionnaires and no PM standardization. PM efficacy and safety need a fundamental re-appraisal by: (i) cohort (retro- and prospective) studies on current users to define its traditional use for rejuvenation; (ii) tightly coupling long-term efficacy to safety of well-defined PM and multiple end-points; (iii) using study design related to current understanding of menopause progression and estrogen pharmacology (iv) robust pharmacovigilance.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Process

  3 / 17301 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29398248
[Au] Autor:Abuhasira R; Schleider LB; Mechoulam R; Novack V
[Ad] Address:Cannabis Clinical Research Institute, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel.
[Ti] Title:Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly.
[So] Source:Eur J Intern Med;49:44-50, 2018 Mar.
[Is] ISSN:1879-0828
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:INTRODUCTION: There is a substantial growth in the use of medical cannabis in recent years and with the aging of the population, medical cannabis is increasingly used by the elderly. We aimed to assess the characteristics of elderly people using medical cannabis and to evaluate the safety and efficacy of the treatment. METHODS: A prospective study that included all patients above 65 years of age who received medical cannabis from January 2015 to October 2017 in a specialized medical cannabis clinic and were willing to answer the initial questionnaire. Outcomes were pain intensity, quality of life and adverse events at six months. RESULTS: During the study period, 2736 patients above 65 years of age began cannabis treatment and answered the initial questionnaire. The mean age was 74.5  7.5 years. The most common indications for cannabis treatment were pain (66.6%) and cancer (60.8%). After six months of treatment, 93.7% of the respondents reported improvement in their condition and the reported pain level was reduced from a median of 8 on a scale of 0-10 to a median of 4. Most common adverse events were: dizziness (9.7%) and dry mouth (7.1%). After six months, 18.1% stopped using opioid analgesics or reduced their dose. CONCLUSION: Our study finds that the therapeutic use of cannabis is safe and efficacious in the elderly population. Cannabis use may decrease the use of other prescription medicines, including opioids. Gathering more evidence-based data, including data from double-blind randomized-controlled trials, in this special population is imperative.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Data-Review

  4 / 17301 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29385020
[Au] Autor:Hebert JR; Forster JE; Stearns-Yoder KA; Penzenik ME; Brenner LA
[Ad] Address:Departments of Physical Medicine and Rehabilitation (Drs Hebert, Forster, and Brenner and Mss Stearns-Yoder and Penzenik) and Neurology (Dr Hebert), University of Colorado, Anschutz Medical Campus, Aurora; Marcus Institute for Brain Health, Anschutz Medical Campus, Aurora, Colorado (Drs Hebert and Brenner and Ms Stearns-Yoder); and VHA Rocky Mountain Mental Illness Research, Education and Clinical Center (MIRECC), Denver, Colorado (Drs Hebert, Forster, and Brenner and Mss Stearns-Yoder and Penzenik).
[Ti] Title:Persistent Symptoms and Objectively Measured Balance Performance Among OEF/OIF Veterans With Remote Mild Traumatic Brain Injury.
[So] Source:J Head Trauma Rehabil;, 2018 Jan 30.
[Is] ISSN:1550-509X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To investigate linear relationships between dizziness, fatigue, and depression and posttraumatic stress disorder (PTSD) and objectively measured balance performance in Veterans with remote mild traumatic brain injury (mTBI). SETTING: Academic laboratory; Veterans Affairs Medical Center. PARTICIPANTS: Thirty Veterans (28 men) who served in Iraq/Afghanistan and whose most recent mTBI was sustained more than 6 months prior to enrollment. DESIGN: Cross-sectional, observational trial. MAIN MEASURES: The Computerized Dynamic Posturography-Sensory Organization Test (CDP-SOT) and the Community Balance and Mobility (CB&M) scale measured balance. Dizziness (Dizziness Handicap Inventory), fatigue (Modified Fatigue Impact Scale), depression-related symptoms (Beck Depression Inventory-II), and PTSD-related symptoms (PTSD Checklist 5) were also measured. RESULTS: Objectively measured balance, CDP-SOT composite, was impaired (mean score of 67.9). CDP-SOT scores correlated with dizziness (r = -0.53; P = .002), fatigue (r = -0.38; P = .03), depression (r = -0.55; P = .001), and PTSD symptoms (r = -0.53; P = .002). Dizziness, time since most recent mTBI, and PTSD symptoms and depression combined explained significant variability in CDP-SOT scores (R = 0.46; P = .003), as did fatigue depression and PTSD symptoms (R = 0.33; P = .01). CONCLUSIONS: Impaired balance was identified among the cohort. Findings suggest that dizziness, fatigue, depression and PTSD, and time since most recent mTBI may influence balance performance. Additional research is needed to identify the potentially interrelated natural histories of these co-occurring symptoms.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1097/HTR.0000000000000385

  5 / 17301 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29377910
[Au] Autor:Ikezono T; Matsumura T; Matsuda H; Shikaze S; Saitoh S; Shindo S; Hasegawa S; Oh SH; Hagiwara Y; Ogawa Y; Ogawa H; Sato H; Tono T; Araki R; Maeda Y; Usami SI; Kase Y
[Ad] Address:Department of Otorhinolaryngology, Saitama Medical University, Saitama, Japan.
[Ti] Title:The diagnostic performance of a novel ELISA for human CTP (Cochlin-tomoprotein) to detect perilymph leakage.
[So] Source:PLoS One;13(1):e0191498, 2018.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Perilymphatic fistula is defined as an abnormal communication between the perilymph-filled space and the middle ear, or cranial spaces. The manifestations include a broad spectrum of neuro-otological symptoms such as hearing loss, vertigo/dizziness, disequilibrium, aural fullness, tinnitus, and cognitive dysfunction. By sealing the fistula, perilymphatic fistula is a surgically correctable disease. Also, appropriate recognition and treatment of perilymphatic fistula can improve a patient's condition and hence the quality of life. However, the difficulty in making a definitive diagnosis due to the lack of an appropriate biomarker to detect perilymph leakage has caused a long-standing debate regarding its management. We have reported a clinical test for the diagnosis of perilymphatic fistula by detecting a perilymph specific protein, Cochlin-tomoprotein, as a diagnostic marker using a western blot. The aim of this study is to establish an ELISA-based human Cochlin-tomoprotein detection test and to evaluate its diagnostic accuracy in clinical subjects. The results of ELISA showed good dilution reproducibility. The mean concentration was 49.79.4 of 10 perilymph samples. The ROC curve in differentiating the perilymph leakage condition from the normal middle ear was significant (P < 0.001) with an area under the curve (AUC) of 0.918 (95% CI 0.824-0.100). We defined the diagnostic criteria as follows: CTP<0.4 negative; 0.4≦CTP<0.8 intermediate; 0.8≦CTP(ng/ml) positive in the clinical usage of the hCTP ELISA, and sensitivity and specificity were 86.4% and 100%, respectively. We further tested the expression specificity of the Cochlin-tomoprotein by testing blood and CSF samples. The concentration was below the detection limit (0.2 ng/ml) in 38 of the 40 blood, and 14 of the 19 CSF samples. We report the accuracy of this test for the diagnosis of perilymphatic fistula. Using ELISA, we can improve the throughput of the test. Furthermore, it is useful for a large-scale study to characterize the clinical picture and delineate the management of this medical condition.
[Mh] MeSH terms primary: Enzyme-Linked Immunosorbent Assay/methods
Extracellular Matrix Proteins/metabolism
Perilymph/metabolism
[Mh] MeSH terms secundary: Blotting, Western
Extracellular Matrix Proteins/blood
Extracellular Matrix Proteins/cerebrospinal fluid
Humans
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (COCH protein, human); 0 (Extracellular Matrix Proteins)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191498

  6 / 17301 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29519159
[Au] Autor:Arnold L; Choy E; Clauw DJ; Oka H; Whalen E; Semel D; Pauer L; Knapp L
[Ad] Address:a University of Cincinnati College of Medicine , 260 Stetson Street, Suite 3200 , Cincinnati , OH 45219 , USA.
[Ti] Title:An evidence-based review of pregabalin for the treatment of fibromyalgia.
[So] Source:Curr Med Res Opin;:1-26, 2018 Mar 09.
[Is] ISSN:1473-4877
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVES: Pregabalin, an α2-δ agonist, is approved for the treatment of fibromyalgia (FM) in the United States, Japan, and 37 other countries. The purpose of this article was to provide an in-depth, evidence-based summary of pregabalin for FM as demonstrated in randomized, placebo-controlled clinical studies, including open-label extensions, meta-analyses, combination studies, and post-hoc analyses of clinical study data. METHODS: PubMed was searched using the term 'pregabalin AND fibromyalgia' and the Cochrane Library with the term 'pregabalin'. Both searches were conducted on 2 March 2017 with no other date limits set. RESULTS: Eleven randomized, double-blind, placebo-controlled clinical studies were identified including parallel group, 2-way crossover, and randomized withdrawal designs. One was a neuroimaging study. Five open-label extensions were also identified. Evidence of efficacy was demonstrated across the studies identified with significant and clinically relevant improvements in pain, sleep quality, and patient status. The safety and tolerability profile of pregabalin is consistent across all the studies identified, including in adolescents, with dizziness and somnolence the most common adverse events reported. These efficacy and safety data are supported by meta-analyses (13 studies). Pregabalin in combination with other pharmacotherapies (7 studies) is also efficacious. Post-hoc analyses have demonstrated the onset of pregabalin efficacy as early as 1-2 days after starting treatment, examined the effect of pregabalin on other aspects of sleep beyond quality, and shown it is effective irrespective of the presence of a wide variety of patient demographic and clinical characteristics. CONCLUSIONS: Pregabalin is a treatment option for FM; its clinical utility has been comprehensively demonstrated.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1080/03007995.2018.1450743

  7 / 17301 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29510461
[Au] Autor:Oskarsson B; Moore D; Mozaffar T; Ravits J; Wiedau-Pazos M; Parziale N; Joyce NC; Mandeville R; Goyal N; Cudkowicz ME; Weiss M; Miller RG; McDonald CM
[Ad] Address:Departments of Neurology and Pathology, University of California, Davis, Sacramento, California.
[Ti] Title:Mexiletine for Muscle Cramps in ALS: A Randomized Double-Blind Crossover Trial.
[So] Source:Muscle Nerve;, 2018 Mar 06.
[Is] ISSN:1097-4598
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:INTRODUCTION: More than 90% of amyotrophic lateral sclerosis (ALS) patients have muscle cramps, and evidence-based treatments have not been available. METHODS: A multicenter double-blind placebo-controlled crossover trial of mexiletine 150 mg twice daily was conducted of ALS patients requesting treatment of symptomatic muscle cramps. RESULTS: Muscle cramp frequency was reduced in 18 of 20 patients; 13 reductions were attributed to treatment (P<.05). The average reduction was 1.8 cramps per day (a reduction from 5.3 with placebo to 3.5 with mexiletine) based on t tests. The estimated reduction of cramp severity was 15 units on a 100-unit scale (P=.01), from a baseline average of 46. No effect on fasciculations was noted. One patient discontinued the study because of dizziness, and another patient discontinued the study to start open-label mexiletine therapy. No serious adverse event occurred. DISCUSSION: Mexiletine is well-tolerated and effective medication for controlling the symptom of muscle cramps in ALS. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1002/mus.26117

  8 / 17301 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29490361
[Au] Autor:Carpenter D; Kaylie D; Piker E; Frank-Ito D
[Ad] Address:Division of Head and Neck Surgery & Communication Sciences, Duke University Medical Center, Durham, NC.
[Ti] Title:A Pilot Study to Investigate the Relationship Between Interaural Differences in Temporal Bone Anatomy and Normal Variations in Caloric Asymmetry.
[So] Source:Am J Audiol;27(1):110-120, 2018 Mar 08.
[Is] ISSN:1558-9137
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Purpose: This study assesses interaural differences in temporal bone anatomy in subjects with normal caloric findings. Method: Eligible patients included those referred to the Duke University Medical Center otology clinic complaining of dizziness, with a head computed tomography scan and caloric stimulation results within normal ranges (inter-ear difference ≤ 10% or < 25% unilateral weakness). Three-dimensional reconstructions of computed tomography scans in 11 patients were used to calculate the surface area and volume of lateral semicircular canals (LSCCs), mastoid airspaces, mastoid bones, and internal auditory canal diameter and circumference. Percent differences in interaural temporal bone anatomy (i.e., left-to-right asymmetry) were analyzed and correlated with warm caloric inter-ear difference (WCD) and clinically indicated caloric predictor asymmetry. Results: A multivariate model predicting WCD from 9 interaural anatomic variables demonstrated a Pearson's coefficient of 0.999. A similarly constructed model of the clinically indicated caloric predictor demonstrated a Pearson's coefficient of 0.999. The univariate correlation was strongest for WCD versus Proctor internal auditory canal diameter (r = 0.476; p = .139) and WCD versus lateral semicircular canal surface-area-to-volume ratio (r = -0.474; p = .141). Conclusions: This pilot study provides multivariate models that predict caloric asymmetry in subjects without vestibular pathologic findings per caloric testing, based on interaural differences across variables of the temporal bone anatomy. Supplemental Material: https://doi.org/10.23641/asha.5895988.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.1044/2017_AJA-16-0048

  9 / 17301 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29467237
[Au] Autor:Lackland DT; Carey RM; Conforto AB; Rosendorff C; Whelton PK; Gorelick PB
[Ad] Address:From the Department of Neurology, Medical University of South Carolina, Charleston (D.T.L.); Department of Medicine, University of Virginia Health System, Charlottesville (R.M.C.); Department of Neurology, Instituto Israelita de Ensino e Pesquisa, Hospital Israelita Albert Einstein, Sao Paulo, Brazi
[Ti] Title:Implications of Recent Clinical Trials and Hypertension Guidelines on Stroke and Future Cerebrovascular Research.
[So] Source:Stroke;49(3):772-779, 2018 03.
[Is] ISSN:1524-4628
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.1161/STROKEAHA.117.019379

  10 / 17301 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29459396
[Au] Autor:Saber Tehrani AS; Kattah JC; Kerber KA; Gold DR; Zee DS; Urrutia VC; Newman-Toker DE
[Ad] Address:From the Department of Neuro-Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston (A.S.S.T.); Department of Neurology, University of Illinois College of Medicine in Peoria (J.C.K.); Department of Neurology, University of Michigan Health System, Ann Arbor (K.A.K.); and D
[Ti] Title:Diagnosing Stroke in Acute Dizziness and Vertigo: Pitfalls and Pearls.
[So] Source:Stroke;49(3):788-795, 2018 03.
[Is] ISSN:1524-4628
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.1161/STROKEAHA.117.016979


page 1 of 1731 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information